By Ben Hirschler MADRID (Reuters) - Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive. The British drugmaker, which fended off a $118 billion (72.64 billion pound) takeover bid from Pfizer in May in part by talking up its cancer drug prospects, has high hopes for the combination of two experimental drugs known as MEDI4736 and tremelimumab. ...
via Health News Headlines - Yahoo News http://ift.tt/1Bl4gdn
No comments:
Post a Comment